Table 4.
Multivariate analysis for predictors of restenosis and mortality at 12 months following CEA.
| Restenosis | Mortality | |||||
|---|---|---|---|---|---|---|
| OR | 95% CI | p-Value | OR | 95% CI | p-Value | |
| Age > 70 | 3.26 | 1.79–5.93 | <0.001 | 5.44 | 1.59–18.60 | 0.007 |
| AH | 2.30 | 1.26–4.19 | 0.006 | 2.13 | 0.77–5.85 | 0.14 |
| IHD | 1.42 | 0.95–2.10 | 0.08 | 1.11 | 0.71–1.73 | 0.64 |
| AF | 1.74 | 1.06–2.87 | 0.02 | 1.26 | 0.85–1.87 | 0.24 |
| MI | 3.16 | 1.83–5.44 | <0.001 | 2.83 | 1.37–5.85 | 0.005 |
| Tobacco | 2.55 | 1.46–4.46 | <0.001 | 2.31 | 0.97–5.50 | 0.058 |
| Obesity | 1.90 | 1.10–3.28 | 0.02 | 1.94 | 0.93–4.05 | 0.07 |
| Dyslipidemia | 5.27 | 3.07–9.02 | <0.001 | 2.80 | 1.37–5.71 | 0.005 |
| Unstable Plaques | 2.83 | 1.67–4.78 | <0.001 | 2.40 | 1.02–5.63 | 0.04 |
| Thrombotic Plaques | 2.77 | 1.57–4.90 | <0.001 | 1.73 | 0.69–4.35 | 0.24 |
| Antiplatelet | 0.46 | 0.27–0.78 | 0.004 | 1.07 | 0.47–2.46 | 0.85 |
| Statins | 0.59 | 0.35–0.78 | 0.04 | 0.75 | 0.32–1.72 | 0.50 |
| Ezetimibe | 0.45 | 0.21–0.95 | 0.03 | 0.74 | 0.24–2.24 | 0.74 |
| high-MLR | 10.37 | 5.38–18.58 | <0.001 | 6.11 | 2.86–13.04 | <0.001 |
| high-NLR | 34.22 | 14.99–78.12 | <0.001 | 37.62 | 12.87–109.97 | <0.001 |
| high-PLR | 12.02 | 6.62–17.88 | <0.001 | 16.06 | 5.78–44.61 | <0.001 |
| high-SII | 18.11 | 9.46–34.66 | <0.001 | 31.70 | 10.37–96.84 | <0.001 |
| high-SIRI | 16.64 | 8.72–31.74 | <0.001 | 9.89 | 4.37–22.37 | <0.001 |
| high-AISI | 16.80 | 8.69–32.45 | <0.001 | 8.24 | 3.76–18.08 | <0.001 |
AH = arterial hypertension; IHD = ischemic heart disease; AF = atrial fibrillation; MI = myocardial infarction; MLR = monocyte-to-lymphocyte ratio; NLR = neutrophil-to-lymphocyte ratio; PLR = platelet-to-lymphocyte ratio; SII = systemic inflammatory index; SIRI = systemic inflammation response index; AISI = aggregate index of systemic inflammation.